Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...

Scientists discovered years ago that the hypothalamus—which helps to manage body temperature, hunger, sex drive, sleep and ...

Palatin Technologies, Inc. (AMEX: PTN) Q2 2025 Earnings Call Transcript February 13, 2025 ...

Scientists discovered years ago that the hypothalamus — which helps to manage body temperature, hunger, sex drive, sleep and ...

Researchers at Brown University and Cincinnati Children's found that suppressing opsin 3 in the brain of mice makes them eat less, raising new ...

Palatin Technologies Inc (PTN) reports reduced net loss and operational cash use, while advancing obesity treatment research ...

Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the stock, ...

Red is the rarest hair color, but to understand why that’s the case, you need a basic grasp of the science. There’s a lot ...

ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, ...

Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report) will likely be announcing its earnings results before the market ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.